Link to full article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma appoints MedPharm to develop new XF‐platform drug formulations MedPharm will develop potential XF‐platform formulations as treatments for dermal and ocular infections Brighton, United Kingdom ‐ 27th March 2019 ‐ Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development […]
Hot on the heels of our first clinical trials approval, Arecor is delighted to be listed in Business Weekly’s ‘Killer50’, as a leading lifescience innovator. Please see the listing and feature here on Page 12: Link
Link to full article Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics $10.0 million of new capital will be invested in combined company to be re-named Armata Pharmaceuticals Preliminary Merger proxy filed with the SEC on March 25, […]
Link to full article Posted on March 25, 2019 Value Proposition of Integrated ADC Manufacturing Processes – Use of Economic Modelling-Poster will be presented at PEGS Boston 2019 , April 8-12. Abstract Development and manufacture of biologic-drug conjugates involves a complex supply chain of multiple, different specialised contracted cGMP facilities. CDMOs have simplified project & contractual arrangements either […]
Link to full article THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or […]
Cambridge, UK., 20 March 2019: Arecor Ltd (“the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im […]
Valencia, Calif., USA, and Melbourne, Australia, 13 March 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that management will present at the Cowen and Company 39th Annual Health Care Conference in Boston. The presentation is being made on 13 March 2019 from 11:20 a.m. to 11:50 a.m. EDT at […]
Cambridge (UK), 11th March 2019, Arecor Limited (‘Arecor’ or the ’Company’), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect […]
Researchers at Kent and Canterbury Hospital, U.K., are recruiting 20 patients with multiple sclerosis (MS) who can walk at least eight meters with a walking aid to test the effectiveness of a five-week exercise program using assistive robotic technology. The Rex device — made by Rex Bionics — is a maneuverable exoskeleton that straps to and supports a […]
COSMOTEC has filed a JPMDA application for approval to market the RECELL System in Japan Valencia, Calif., USA, and Melbourne, Australia, 4 March 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that it has collaborated with COSMOTEC, an M3 Group company, to market and distribute the RECELL® Autologous Cell […]